Literature DB >> 11966333

Differences in cardiovascular disease risk between nondiabetic adults with mental retardation with and without Down syndrome.

Christopher C Draheim1, Jeffrey A McCubbin, Daniel P Williams.   

Abstract

A reduced expression of the insulin resistance syndrome, a common neuroendocrine disorder underlying atherosclerosis, may play a role in reduced atherosclerosis in adults with Down syndrome. We compared selected components of the insulin resistance syndrome between 75 adults with Down syndrome and 70 with mental retardation due to other causes. After adjusting for age differences, residence, cigarette smoking, and medication use, women with Down syndrome had lower fasting plasma glucose and lower systolic blood pressure than comparison women. Men with Down syndrome had lower systolic and diastolic blood pressure than comparison men. Results suggest that women with Down syndrome may be less likely to express the insulin resistance syndrome, and men and women with Down syndrome may possess fewer atherosclerotic risk factors than the comparison groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966333     DOI: 10.1352/0895-8017(2002)107<0201:DICDRB>2.0.CO;2

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  26 in total

1.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

Review 2.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

Review 3.  Screening tests for adults with intellectual disabilities.

Authors:  Joanne E Wilkinson; Larry Culpepper; Mary Cerreto
Journal:  J Am Board Fam Med       Date:  2007 Jul-Aug       Impact factor: 2.657

Review 4.  Functional genetic variation of human miRNAs and phenotypic consequences.

Authors:  Christelle Borel; Stylianos E Antonarakis
Journal:  Mamm Genome       Date:  2008-09-12       Impact factor: 2.957

5.  Prediction of oxygen uptake during over-ground walking in people with and without Down syndrome.

Authors:  Stamatis Agiovlasitis; Robert W Motl; Sushant M Ranadive; Christopher A Fahs; Huimin Yan; George H Echols; Lindy Rossow; Bo Fernhall
Journal:  Eur J Appl Physiol       Date:  2011-01-09       Impact factor: 3.078

6.  Effectiveness of a HealthMessages Peer-to-Peer Program for People With Intellectual and Developmental Disabilities.

Authors:  Beth Marks; Jasmina Sisirak; Rubia Magallanes; Kristin Krok; Dina Donohue-Chase
Journal:  Intellect Dev Disabil       Date:  2019-06

7.  Cardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  Int J Hypertens       Date:  2010-08-04       Impact factor: 2.420

8.  Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes.

Authors:  Praveen Sethupathy; Christelle Borel; Maryline Gagnebin; Gregory R Grant; Samuel Deutsch; Terry S Elton; Artemis G Hatzigeorgiou; Stylianos E Antonarakis
Journal:  Am J Hum Genet       Date:  2007-07-12       Impact factor: 11.025

9.  Peripheral blood flow regulation in response to sympathetic stimulation in individuals with Down syndrome.

Authors:  Thessa I M Hilgenkamp; Sang Ouk Wee; Elizabeth C Schroeder; Tracy Baynard; Bo Fernhall
Journal:  Artery Res       Date:  2018-10-24       Impact factor: 0.597

10.  Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.

Authors:  Daishi Hirano; Saori Miwa; Daisuke Kakegawa; Chisato Umeda; Yoichi Takemasa; Ai Tokunaga; Kawakami Yuhei; Akira Ito
Journal:  Pediatr Nephrol       Date:  2021-01-19       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.